- A 2026 review summarised the safety profile of GLP-1 receptor agonists and related incretin therapies used for type 2 diabetes and obesity.
- The most common problems are gastrointestinal and often manageable, but there are important edge cases around gallbladder disease, thyroid cancer risk in susceptible groups, and eye complications in specific contexts.
- The right approach is informed use: dose carefully, manage side effects early, and monitor the people who need monitoring.
Why GLP-1s are so widely used
GLP-1 medicines work through multiple mechanisms: they enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
In many people they improve HbA1c and support clinically meaningful weight loss, which is why they have changed the landscape for type 2 diabetes care.
Common side effects and how to reduce them
Gastrointestinal side effects are the main reason people stop treatment.
Typical issues include nausea, vomiting, constipation and diarrhoea.
What usually helps:
- Slower titration and patience with dose increases
- Smaller meals and avoiding very fatty meals during escalation
- Prioritising protein and fibre, which can reduce “empty stomach nausea”
- Hydration, particularly if diarrhoea occurs
The review explicitly discusses the impact of side effects on persistence and highlights the need for mitigation strategies.
Gallbladder and biliary disease
The review notes evidence suggesting increased biliary disease risk such as gallstones, particularly in the context of weight loss and altered bile handling.
The practical point is symptom awareness: upper right abdominal pain, jaundice, fever, or persistent vomiting needs prompt assessment.
Pancreatitis and pancreatic cancer
Earlier concerns about pancreatitis and pancreatic cancer have been largely dispelled by long-term randomised trial evidence, according to the review.
That said, ongoing pharmacovigilance still matters because diagnosing pancreatitis is not always straightforward.
Thyroid cancer risk and contraindications
Rodent findings triggered longstanding concerns about medullary thyroid carcinoma.
The review notes that GLP-1 receptor expression patterns differ between species and that absolute event numbers are low, but it still treats at-risk status as clinically important.
If you have a personal or family history relevant to medullary thyroid carcinoma, or related endocrine syndromes, this needs explicit clinician discussion before use.
Eyes, retinopathy, and UK screening reality
Rapid improvement in glycaemic control can sometimes cause early worsening of diabetic retinopathy, regardless of the method.
Semaglutide trials raised attention to retinopathy complications in certain contexts, likely concentrated in people with pre-existing eye disease and large HbA1c drops.
In the UK, NHS diabetic eye screening guidance has not required extra screening purely because someone starts a GLP-1 or has rapid improvement, but if someone has missed their last screening and is about to start treatment, they can be re-invited on request.
The practical advice is simple: keep your eye screening up to date and report visual changes promptly.
- Weight loss surgery outperforms GLP-1 drugs in real-world use
- GLP-1 weight loss injections: when side effects become emergencies
When to seek urgent medical help
Seek urgent advice if you develop:
- Severe persistent abdominal pain, especially with vomiting
- Signs of dehydration you cannot correct with fluids
- Jaundice or fever
- Sudden visual changes
